Skip to main navigation
Top Links - Left
BioNTech.com
Newsroom
Investors
Healthcare Professionals
English
Language switcher (Content)
English
German
Top Links - Right
Connect
Main Navigation
BioNTech.com
News
Events & Presentations
Financials
Financials
SEC Filings
Annual Reports
Quarterly Reports
Financial Calendar
Corporate Governance
Corporate Governance
Overview
Transparency
ESG
Stock Info
Stock Info
Stock Quote & Chart
Analyst Coverage
Shareholder Fraud Warning
Share Repurchase Program
Dividend Information
Investor FAQs
Annual General Meeting
Annual General Meeting
Annual General Meeting 2024
Annual General Meeting Archive
Contact Us
Newsroom
Investors
Healthcare Professionals
Breadcrumb
Investors
Search
Search
Filter by content type
(-)
News
(15)
Filter by content year
(-)
2022
(15)
Filter by form group
Filter by category
(-)
Science
(15)
Collaborators
(13)
Clinical
(10)
Events
(2)
Filter by category
Search
News
Pfizer und BioNTech veröffentlichen Daten zu starker Immunantwort nach Auffrischungsimpfung mit dem COVID-19-Impfstoff bei Kindern im Alter von 5 bis 11 Jahren
News
Pfizer and BioNTech Announce Data Demonstrating High Immune Response Following a Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Age
News
BioNTech präsentiert erste positive Daten der Phase-1/2-Studie mit erstem CAR-T-Programm BNT211 auf der AACR
News
BioNTech Presents Positive Preliminary Phase 1/2 Data for First-in-Class CAR-T Program BNT211 at AACR
News
Pfizer and BioNTech Publish Data from Two Laboratory Studies on COVID-19 Vaccine-induced Antibodies Ability to Neutralize SARS-CoV-2 Omicron Variant
Pagination
Previous page
‹‹
Page 2